personalized live-attenuated double-deleted Listeria monocytogenes
Term · Oncology and biomedicine · MLC-T-ONC-015976
A proprietary, personalized live, attenuated, double-deleted (pLADD) strain of the Gram-positive bacterium Listeria monocytogenes encoding multiple, patient-specific neoantigens, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, the tumor-associated antigens (TAAs) expressed in pLADD are taken up by antigen-presenting cells (APCs), including dendritic cells (DCs), and are processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to both an innate immune response and the recruitment and activation of tumor-specific cytotoxic T lymphocytes (CTLs) against the TAAs specifically expressed by the patient's tumor cells, which eventually results in tumor cell lysis.
| Identifier | MLC-T-ONC-015976 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | pLADD |
| Synonyms | personalized LADD; patient-specific LADD |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015976",
"term": "personalized live-attenuated double-deleted Listeria monocytogenes",
"field": "Oncology and biomedicine",
"definition": "A proprietary, personalized live, attenuated, double-deleted (pLADD) strain of the Gram-positive bacterium Listeria monocytogenes encoding multiple, patient-specific neoantigens, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, the tumor-associated antigens (TAAs) expressed in pLADD are taken up by antigen-presenting cells (APCs), including dendritic cells (DCs), and are processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to both an innate immune response and the recruitment and activation of tumor-specific cytotoxic T lymphocytes (CTLs) against the TAAs specifically expressed by the patient's tumor cells, which eventually results in tumor cell lysis.",
"abbreviation": "pLADD",
"synonyms": [
"personalized LADD",
"patient-specific LADD"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/personalized-live-attenuated-double-deleted-listeria-monocytogenes/"
}
Record 13,016 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.